Outlook Therapeutics Announces FDA Approval of LYTENAVA for Wet AMD

What Happened
Outlook Therapeutics, Inc. (OTLK) announced on July 24, 2026 that the U.S. Food and Drug Administration approved the company’s biologics license application (BLA) for ONS-5010/LYTENAVA™ (bevacizumab-vikg), an ophthalmic formulation of bevacizumab, for the treatment of neovascular (wet) age-related macular degeneration (wet AMD). The company stated that LYTENAVA™ is the first and only FDA-approved ophthalmic formulation of bevacizumab for wet AMD in the United States. The company attached a press release dated July 24, 2026 as Exhibit 99.1 to the Form 8-K.

Key Details

• FDA approval date announced: July 24, 2026.
• Product: ONS-5010 / LYTENAVA™ (bevacizumab-vikg), ophthalmic bevacizumab.
• Indication: Treatment of neovascular (wet) age-related macular degeneration (wet AMD).
• Company filed the press release as Exhibit 99.1 to the Current Report on Form 8-K.

Why It Matters
FDA approval is a regulatory milestone that authorizes Outlook Therapeutics to market LYTENAVA™ in the U.S. for the approved indication, which can be a pivotal step toward commercialization. For investors, this development represents a material change in the company’s product and regulatory status, as LYTENAVA™ is identified as the first FDA-approved ophthalmic bevacizumab for wet AMD in the U.S., potentially affecting Outlook’s competitive positioning in the ophthalmology market.